Compound profile

Methenolone

Also known as Primobolan, Primo, Methenolone enanthate, Methenolone acetate

Not approved
  • Anabolic steroids
  • Oral (tablet)
  • DHT derivative

Last reviewed October 2026

Educational only. A summary of published research, not medical advice or a recommendation. No doses are listed.

Quick take

A DHT-derived steroid, injected or taken as a tablet, often described by users as mild, though it still shuts down natural testosterone and worsens cholesterol.

Class
Anabolic steroids
Status
Not approved
Evidence
Early or small human studies
Half-life
Not well documented

Mechanism fingerprint

What it acts on, and how. Each chip links to that pathway on the map.

A DHT derivative that doesn't convert to estrogen. Unlike most oral steroids, the tablet form isn't 17α-alkylated.

What makes it different

A DHT derivative whose tablet form isn't 17α-alkylated, unlike most oral steroids.

Compare side by side

Mechanism & pathways

Methenolone
  • Agonist Androgen receptor

    Receptor for testosterone and DHT. Activating it builds muscle and drives male traits such as body hair and a deeper voice. Every anabolic steroid binds it.

See Methenolone on the pathway map

Evidence overview

Early or small human studies

Older clinical use and studies outside the US; no modern trials.

A breakdown into human, animal and cell studies hasn't been added for this compound yet.

Why it's used

Medically, it was used in some countries for muscle wasting and anemia. Bodybuilders use it for slow, lean gains without estrogen-related side effects such as water retention.

Side effects & risks

Reported side effects

  • Hair loss in people prone to it
  • Acne
  • Lower HDL (“good”) cholesterol

Risks and warnings

  • Shuts down the body's own testosterone production: testicles shrink and sperm counts fall, and recovery after stopping can take months or be incomplete.
  • Lowers HDL (“good”) cholesterol and raises LDL, adding to heart disease risk.
  • Long-term use is linked to high blood pressure, heart muscle damage (cardiomyopathy), heart attacks and early death.
  • In women: masculinizing effects (deeper voice, facial and body hair, clitoral enlargement) that can be permanent.
  • Underground-lab products are often mislabeled or contaminated, and non-sterile injections can cause abscesses and infections.
  • Schedule III controlled substance in the US: illegal to possess without a prescription.
  • Prohibited in sport by the World Anti-Doping Agency (WADA).

FAQ

Short answers taken from this profile.

What is Methenolone?

A DHT-derived steroid, injected or taken as a tablet, often described by users as mild, though it still shuts down natural testosterone and worsens cholesterol.

How does Methenolone work?

A DHT derivative that doesn't convert to estrogen. Unlike most oral steroids, the tablet form isn't 17α-alkylated.

What receptors or pathways does Methenolone act on?

androgen receptor (agonist).

How is Methenolone different from similar compounds?

A DHT derivative whose tablet form isn't 17α-alkylated, unlike most oral steroids.

Is Methenolone approved?

Never approved in the US; sold as a prescription medicine in some other countries in the past.

What has Methenolone been studied for?

Medically, it was used in some countries for muscle wasting and anemia. Bodybuilders use it for slow, lean gains without estrogen-related side effects such as water retention.

How strong is the evidence?

Early or small human studies. Older clinical use and studies outside the US; no modern trials.

What are the main risks?

Shuts down the body's own testosterone production: testicles shrink and sperm counts fall, and recovery after stopping can take months or be incomplete. Lowers HDL (“good”) cholesterol and raises LDL, adding to heart disease risk. Long-term use is linked to high blood pressure, heart muscle damage (cardiomyopathy), heart attacks and early death. More are listed under risks and warnings.

Sources

  • Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol 2008.
  • Pope HG et al. Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocr Rev 2014.